TANVEX BIOPHARMA, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.8 TWD | +1.42% |
|
-1.50% | -34.25% |
| 03-14 | Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-06 | Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 15,167 | 10,921 | 9,894 | 20,476 | 12,377 | 8,715 |
| Enterprise Value (EV) 1 | 11,640 | 8,837 | 9,345 | 20,012 | 13,430 | 10,066 |
| P/E ratio | -7.51 x | -4.83 x | -4.77 x | -12.3 x | -7.54 x | -3.93 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 32,979,064,153 x | 3,787,620,245 x | 552,427,217 x | 141,906,749 x |
| EV / Revenue | - | - | 31,148,420,820 x | 3,701,798,750 x | 599,427,887 x | 163,906,538 x |
| EV / EBITDA | -6.4 x | -4.05 x | -4.77 x | -13.4 x | -9 x | -5.09 x |
| EV / FCF | -11.3 x | -7.33 x | -8.69 x | -24.4 x | -15.9 x | -14.1 x |
| FCF Yield | -8.87% | -13.6% | -11.5% | -4.09% | -6.29% | -7.08% |
| Price to Book | 3.6 x | 3.9 x | 4.45 x | 7.33 x | 8.9 x | 10.6 x |
| Nbr of stocks (in thousands) | 80,949 | 81,410 | 88,244 | 117,561 | 117,623 | 133,865 |
| Reference price 2 | 187.4 | 134.2 | 112.1 | 174.2 | 105.2 | 65.10 |
| Announcement Date | 3/28/19 | 3/27/20 | 3/30/21 | 3/28/22 | 3/8/23 | 3/14/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | 0.3 | 5.406 | 22.4 | 61.41 |
| EBITDA 1 | -1,818 | -2,183 | -1,958 | -1,496 | -1,492 | -1,976 |
| EBIT 1 | -1,951 | -2,328 | -2,100 | -1,599 | -1,606 | -2,101 |
| Operating Margin | - | - | -699,859% | -29,581.65% | -7,166.21% | -3,420.8% |
| Earnings before Tax (EBT) 1 | -1,894 | -2,274 | -2,104 | -1,543 | -1,641 | -2,137 |
| Net income 1 | -1,894 | -2,274 | -2,104 | -1,543 | -1,641 | -2,137 |
| Net margin | - | - | -701,412% | -28,546.26% | -7,325.17% | -3,480% |
| EPS 2 | -24.94 | -27.76 | -23.51 | -14.21 | -13.95 | -16.58 |
| Free Cash Flow 1 | -1,032 | -1,205 | -1,075 | -819.1 | -844.2 | -713.1 |
| FCF margin | - | - | -358,247.62% | -15,152.23% | -3,768.22% | -1,161.12% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/28/19 | 3/27/20 | 3/30/21 | 3/28/22 | 3/8/23 | 3/14/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 |
|---|---|---|---|---|
| Net sales 1 | 4.844 | - | 3.044 | 8.33 |
| EBITDA | -271.4 | - | - | - |
| EBIT 1 | -337.2 | - | -417.7 | -391.6 |
| Operating Margin | -6,961.09% | - | -13,722.86% | -4,700.85% |
| Earnings before Tax (EBT) 1 | -350.6 | - | -427 | -404.2 |
| Net income 1 | -350.6 | -331.8 | -427.1 | -404.2 |
| Net margin | -7,238.63% | - | -14,029.47% | -4,852.57% |
| EPS 2 | -2.908 | -2.818 | -3.627 | -3.447 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 3/28/22 | 5/13/22 | 8/30/22 | 11/14/22 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 1,053 | 1,351 |
| Net Cash position 1 | 3,527 | 2,085 | 549 | 464 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.7056 x | -0.6838 x |
| Free Cash Flow 1 | -1,032 | -1,205 | -1,075 | -819 | -844 | -713 |
| ROE (net income / shareholders' equity) | -47.6% | -62.8% | -74.5% | -57% | -78.4% | -193% |
| ROA (Net income/ Total Assets) | -28.8% | -36.1% | -33% | -22% | -24.7% | -42.5% |
| Assets 1 | 6,565 | 6,292 | 6,371 | 7,015 | 6,651 | 5,032 |
| Book Value Per Share 2 | 52.00 | 34.40 | 25.20 | 23.80 | 11.80 | 6.130 |
| Cash Flow per Share 2 | 20.10 | 27.50 | 19.90 | 18.90 | 6.680 | 2.840 |
| Capex 1 | 105 | 89.1 | 66 | 29.8 | 93.5 | 71 |
| Capex / Sales | - | - | 22,009.67% | 551.68% | 417.35% | 115.64% |
| Announcement Date | 3/28/19 | 3/27/20 | 3/30/21 | 3/28/22 | 3/8/23 | 3/14/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -34.25% | 214M | |
| +7.52% | 111B | |
| +11.38% | 106B | |
| -12.64% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.58% | 16.81B | |
| +37.41% | 12.54B | |
| -23.95% | 8.09B |
- Stock Market
- Equities
- 6541 Stock
- Financials Tanvex BioPharma, Inc.